Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.

SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Bioverativ Inc., and Juno Therapeutics, Inc., as detailed below:

Bioverativ Inc.
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Bioverativ Inc. (NASDAQ: BIVV) ("Bioverativ ") breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NYSE: SNY).

On January 22, 2018, Bioverativ announced that it had signed a definitive merger agreement with Sanofi. Under the terms of the agreement, Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash.

The investigation concerns whether the Bioverativ board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Bioverativ shares of common stock, especially given the Company's projected revenue and earnings growth.

If you are a shareholder of Bioverativ and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

.

Juno Therapeutics, Inc.
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Juno Therapeutics, Inc. (NASDAQ: JUNO) ("Juno") breached their fiduciary duties in connection with the proposed sale of the Company to Celgene Corporation.

On January 22, 2018, Juno announced that it had signed a definitive merger agreement with Celgene. Under the terms of the agreement, Celgene will acquire all of the outstanding shares of Juno for $87 per share in cash.

The investigation concerns whether the Juno board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Juno shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given that the one Wall Street analyst has a $98.00 price target on the stock.

If you are a shareholder of Juno and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

View original content:http://www.prnewswire.com/news-releases/johnson-fistel-announces-investigations-of-the-proposed-sales-of-bioverativ-inc-and-juno-therapeutics-inc-300585805.html

SOURCE Johnson Fistel, LLP